---
title: "Today, the drugs developed by Astrazeneca and Sanofi for the prevention of infant RSV infection have been approved in China."
description: "The drug Levoi® (nirsevimab), jointly developed by AstraZeneca and Sanofi, has been approved for market by the China National Medical Products Administration. This drug can prevent infant RSV infectio"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/105271816.md"
published_at: "2024-01-02T11:14:06.000Z"
---

# Today, the drugs developed by Astrazeneca and Sanofi for the prevention of infant RSV infection have been approved in China.

> The drug Levoi® (nirsevimab), jointly developed by AstraZeneca and Sanofi, has been approved for market by the China National Medical Products Administration. This drug can prevent infant RSV infection, which is one of the main causes of infant hospitalization. Nirsevimab has already been approved in the European Union and the United States, and is expected to be launched in China in 2024-2025. AstraZeneca and Sanofi have collaborated on the development, production, and commercialization of this drug.

Zhitong App learned today that Astrazeneca and Sanofi have announced the official approval and launch of their jointly developed and commercialized long-acting monoclonal antibody, Nirsevimab, by the China National Medical Products Administration.

This drug is used to prevent lower respiratory tract infections (LRTIs) caused by respiratory syncytial virus (RSV) in newborns and infants. RSV is a common and highly contagious seasonal virus that is the most common cause of lower respiratory tract infections in infants, such as bronchiolitis and pneumonia, and is also one of the main reasons for infant hospitalization. Data shows that RSV ranks among the top three pathogens causing viral respiratory infections in children and may lead to mixed outbreaks of various respiratory viruses.

It is reported that China is one of the countries with a high prevalence of RSV worldwide. Nirsevimab is expected to be launched in China during the RSV infection season in 2024-2025.

Nirsevimab was approved in the European Union in October 2022 and subsequently received approval from the U.S. Food and Drug Administration (FDA) in July 2023 based on the unanimous recommendation of the Antimicrobial Drugs Advisory Committee. Currently, the marketing applications for Nirsevimab submitted in Japan and several other markets are also under review.

AstraZeneca and Sanofi announced their collaboration on the development and commercialization of Nirsevimab in March 2017. Under the terms of the agreement, AstraZeneca is responsible for product development and production, while Sanofi is responsible for commercialization and revenue measurement. Both companies share costs and profits in all regions except the United States. The revenue AstraZeneca receives based on this agreement is classified as alliance revenue and collaboration revenue in the company's financial statements.

### Related Stocks

- [SNYNF.US - Sanofi](https://longbridge.com/en/quote/SNYNF.US.md)
- [AZN.UK - AstraZeneca PLC](https://longbridge.com/en/quote/AZN.UK.md)
- [SNY.US - Sanofi](https://longbridge.com/en/quote/SNY.US.md)
- [TBIO.US - Telesis Bio](https://longbridge.com/en/quote/TBIO.US.md)
- [AZN.US - AstraZeneca](https://longbridge.com/en/quote/AZN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Select 医药控股｜10-K：2025 财年营收 54.53 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276384073.md) |
| 中国环球资产管理有限公司持有价值 1025 万美元的阿斯利康股份 $AZN | 中国泛华资产管理有限公司在第三季度减少了对阿斯利康制药的持股比例，下降了 10.4%，目前持有 133,580 股，市值为 1025 万美元。这使得阿斯利康占其总持股的 0.8%。其他对冲基金也调整了他们的持仓，几家显著增加了他们的持股比例 | [Link](https://longbridge.com/en/news/276435119.md) |
| 阿斯利康称，美国 FDA 已批准 Calquence 组合疗法用于特定血癌患者 | 阿斯利康表示，美国 FDA 批准 Calquence 联合疗法用于某些血癌患者 | [Link](https://longbridge.com/en/news/276444179.md) |
| 安大略教师养老金计划委员会出售了阿斯利康公司（AstraZeneca PLC）的$AZN 股票 | 安大略教师退休金计划委员会在第三季度将其在阿斯利康（AstraZeneca PLC，NASDAQ:AZN）的持股减少了 41%，目前持有 817,880 股，价值 6270 万美元。其他机构投资者也调整了他们的持仓，加拿大帝国商业银行世界市 | [Link](https://longbridge.com/en/news/276339476.md) |
| 德克萨斯州起诉赛诺菲，指控其涉嫌通过'贿赂'医疗服务提供者来增加药品处方量 | 德克萨斯州检察长肯·帕克斯顿已对赛诺菲提起诉讼，指控该公司贿赂医疗服务提供者以推广其药物。诉讼称，赛诺菲的项目违反了德克萨斯州医疗保健计划欺诈预防法。帕克斯顿寻求超过一百万美元的经济赔偿和对进一步非法行为的禁令。这是继对赛诺菲及其他公司因类 | [Link](https://longbridge.com/en/news/276391061.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
